Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway

Cisplatin represents one of the first‐line drugs used for non‐small‐cell lung cancer treatment. However, considerable side effects and the emergence of drug resistance are becoming critical limitations to its application. Combinatorial strategies may be able to extend the use of cisplatin. Both Tans...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Phytother Res
Prif Awduron: Liao, Xiao‐Zhong, Gao, Ying, Huang, Sheng, Chen, Zhuang‐Zhong, Sun, Ling‐Ling, Liu, Jia‐Hui, Chen, Han‐Rui, Yu, Ling, Zhang, Jia‐Xing, Lin, Li‐Zhu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2019
Pynciau:
Research Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6772065/
https://ncbi.nlm.nih.gov/pubmed/31268205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ptr.6392
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg